Low cancer stem cell marker expression and low hypoxia identify good prognosis subgroups in HPV(-) HNSCC after postoperative radiochemotherapy: A multicenter study of the DKTK-ROG

Clinical Cancer Research

Volumn 22, Issue 11, 2016, Pages 2639-2649

  Linge, Annett ^a,b   Lock, Steffen ^b   Gudziol, Volker ^b   Nowak, Alexander ^b   Lohaus, Fabian ^a,b   Von Neubeck, Clare ^a,b   Jutz, Martin ^b   Abdollahi, Amir ^a,c,d   Debus, Jurgen ^a,e   Tinhofer, Inge ^a,e   Budach, Volker ^a,f   Sak, Ali ^a,f   Stuschke, Martin ^a,g   Balermpas, Panagiotis ^a,g   Rodel, Claus ^a,h   Avlar, Melanie ^a,h   Grosu, Anca Ligia ^a   Bayer, Christine ^a,i   Belka, Claus ^a,j   Pigorsch, Steffi ^a,j   Combs, Stephanie E ^a,j   Welz, Stefan ^a,k   Zips, Daniel ^a,k   Buchholz, Frank ^a,b   Aust, Daniela E ^a,b   Baretton, Gustavo B ^a,b   Thames, Howard D ^l   Dubrovska, Anna ^a,b   Alsner, Jan ^m   Overgaard, Jens ^m   Baumann, Michael ^a,b,n   Krause, Mechthild ^a,b,n   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Heidelberg Institute of Radiation Oncology (HIRO)   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

^g GOETHE UNIVERSITY   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ UNIVERSITY OF MUNICH   (Germany)

^j TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^k UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^m AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁿ INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; HERMES ANTIGEN; SCATTER FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; CD44 PROTEIN, HUMAN; CD98 ANTIGEN; HYALURONIC ACID BINDING PROTEIN; SLC3A2 PROTEIN, HUMAN; TRANSCRIPTOME; TUMOR MARKER;

ARTICLE; CANCER CONTROL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STEM CELL; CD44 GENE; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; GENE; GENE EXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; HYPOXIA; MAJOR CLINICAL STUDY; MET GENE; MULTICENTER STUDY (TOPIC); POSTOPERATIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SLC3A2 GENE; CELL HYPOXIA; CLINICAL TRIAL; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MOUTH TUMOR; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CHEMORADIOTHERAPY; CISPLATIN; FUSION REGULATORY PROTEIN 1, HEAVY CHAIN; HUMAN PAPILLOMAVIRUS 16; HUMANS; HYALURONAN RECEPTORS; KAPLAN-MEIER ESTIMATE; MOUTH NEOPLASMS; MULTIVARIATE ANALYSIS; NEOPLASTIC STEM CELLS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; PROSPECTIVE STUDIES; TRANSCRIPTOME; TREATMENT OUTCOME;

EID: 84962316840     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1990     Document Type: Article

References (50)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
2. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9-22.
3. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-52.
4. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937-44.
5. Fietkau R, Lautenschlager C, Sauer R, Dunst J, Becker A, Baumann M, et al. Postoperative concurrent radiochemotherapy versus radiotherapy in highrisk SCCA of the head and neck: results of the German phase III trial ARO 96-3. J Clin Oncol 2006;24 (suppl18):5507.
6. Lohaus F, Linge A, Tinhofer I, Budach V, Gkika E, Stuschke M, et al. HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiother Oncol 2014;113:317-23.
7. Kimple RJ, Smith MA, Blitzer GC, Torres AD, Martin JA, Yang RZ, et al. Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res 2013;73:4791-800.
8. Gupta AK, Lee JH, Wilke WW, Quon H, Smith G, Maity A, et al. Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT. Int J Radiat Oncol Biol Phys 2009;74:928-33.
9. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149-56.
10. Overgaard J. Hypoxic radiosensitization: Adored and ignored. J Clin Oncol 2007;25:4066-74.
11. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-9.
12. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al.. An international multi-center study. Radiother Oncol 2005;77:18-24. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy.
13. Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol 2012;105:14-20.
14. Zips D, Zophel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, et al. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol 2012;105:21-8.
15. Toustrup K, Sorensen BS, Nordsmark M, Busk M, Wiuf C, Alsner J, et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res 2011;71:5923-31.
16. Eustace A, Mani N, Span PN, Irlam JJ, Taylor J, Betts GN, et al. A 26- gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. Clin Cancer Res 2013;19:4879-88.
17. Lendahl U, Lee KL, Yang H, Poellinger L. Generating specificity and diversity in the transcriptional response to hypoxia. Nat Rev Genet 2009;10:821-32.
18. Buffa FM, Harris AL, West CM, Miller CJ. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 2010;102:428-35.
19. Gronroos TJ, Lehtio K, Soderstrom KO, Kronqvist P, Laine J, Eskola O, et al. Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: Correlations between multiple immunohistochemical parameters and PET. BMC Cancer 2014;14:876.
20. Yaromina A, Thames H, Zhou X, Hering S, Eicheler W, Dorfler A, et al. Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. Radiother Oncol 2010;96:116-22.
21. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, JonesDL, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339-44.
22. Baumann M, Krause M, Thames H, Trott K, Zips D. Cancer stem cells and radiotherapy. Int J Radiat Biol 2009;85:391-402.
23. Hill RP, Milas L. The proportion of stem cells in murine tumors. Int J Radiat Oncol Biol Phys 1989;16:513-8.
24. Petersen C, Zips D, Krause M, Schone K, Eicheler W, Hoinkis C, et al. Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. Int J Radiat Oncol Biol Phys 2001;51:483-93.
25. Petersen C, Zips D, Krause M, Volkel W, Thames HD, Baumann M. Recovery from sublethal damage during fractionated irradiation of human FaDu SCC. Radiother Oncol 2005;74:331-6.
26. ThamesHDJr, Withers HR, Peters LJ, FletcherGH. Changes in early and late radiation responses with altered dose fractionation: Implications for dosesurvival relationships. Int J Radiat Oncol Biol Phys 1982;8:219-26.
27. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008;26:317-25.
28. Snietura M, Piglowski W, Jaworska M, Mucha-Malecka A, Wozniak G, Lange D, et al. Impact of HPV infection on the clinical outcome of p-CAIR trial in head and neck cancer. Eur Arch Otorhinolaryngol 2011;268:721-6.
29. Heiduschka G, Grah A, Oberndorfer F, Kadletz L, Altorjai G, Kornek G, et al. Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy. Strahlenther Onkol 2015;191: 209-16.
30. Butof R, Dubrovska A, Baumann M. Clinical perspectives of cancer stem cell research in radiation oncology. Radiother Oncol 2013;108:388-96.
31. Hill RP, Marie-Egyptienne DT, Hedley DW. Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 2009;19:106-11.
32. Mohyeldin A, Garzon-Muvdi T, Quinones-Hinojosa A.Oxygen in stem cell biology: A critical component of the stem cell niche. Cell Stem Cell 2010;7:150-61.
33. Peitzsch C, Perrin R, Hill RP, Dubrovska A, Kurth I. Hypoxia as a biomarker for radioresistant cancer stem cells. Int J Radiat Biol 2014;90:636-52.
34. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008;8:545-54.
35. Kim Y, Lin Q, Zelterman D, Yun Z. Hypoxia-regulated delta-like 1 homologue enhances cancer cell stemness and tumorigenicity. Cancer Res 2009;69:9271-80.
36. Brunner TB, Kunz Schughart LA, Grosse Gehling P, Baumann M. Cancer stem cells as a predictive factor in radiotherapy. Semin Radiat Oncol 2012;22:151-74.
37. Faber A, Barth C, Hormann K, Kassner S, Schultz JD, Sommer U, et al. CD44 as a stem cell marker in head and neck squamous cell carcinoma. Oncol Rep 2011;26:321-6.
38. de Jong MC, Pramana J, van der Wal JE, Lacko M, Peutz-Kootstra CJ, de Jong JM, et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res 2010;16:5329-38.
39. Martens-de Kemp SR, Brink A, Stigter-van Walsum M, Damen JM, Rustenburg F, Wu T, et al. CD98 marks a subpopulation of head and neck squamous cell carcinoma cells with stem cell properties. Stem Cell Res 2013;10:477-88.
40. Rietbergen MM, Martens-de Kemp SR, Bloemena E, Witte BI, Brink A, Baatenburg de Jong RJ, et al. Cancer stem cell enrichment marker CD98: A prognostic factor for survival in patients with human papillomaviruspositive oropharyngeal cancer. Eur J Cancer 2014;50:765-73.
41. Lim YC, Kang HJ, Moon JH. C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell. Oral Oncol 2014;50:633-9.
42. Sun S, Liu S, Duan SZ, Zhang L, Zhou H, Hu Y, et al. Targeting the c-Met/FZD8 signaling axis eliminates patient-derived cancer stem-like cells in head and neck squamous carcinomas. Cancer Res 2014;74:7546-59.
43. Baschnagel AM, Williams L, Hanna A, Chen PY, Krauss DJ, Pruetz BL, et al. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation. Int J Radiat Oncol Biol Phys 2014;88: 701-7.
44. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61.
45. Clatot F, Gouerant S, Mareschal S, Cornic M, Berghian A, Choussy O, et al. The gene expression profile of inflammatory, hypoxic and metabolic genes predicts the metastatic spread of human head and neck squamous cell carcinoma. Oral Oncol 2014;50:200-7.
46. Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 2007;26:319-31.
47. Chan DA, Giaccia AJ. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 2007;26:333-9.
48. Krause M, Yaromina A, Eicheler W, Koch U, Baumann M. Cancer stem cells: Targets and potential biomarkers for radiotherapy. Clin Cancer Res 2011;17:7224-9.
49. Baumann M, Krause M. CD44: A cancer stem cell-related biomarker with predictive potential for radiotherapy. Clin Cancer Res 2010;16:5091-3.
50. Kimple RJ, Harari PM. The prognostic value of HPVin head and neck cancer patients undergoing postoperative chemoradiotherapy. Ann Transl Med 2015;3:S14. www.